Showing 1-10 of 1407 results for "".

• Study Shows Promise for LRRK2 Inhibitor Approach to Parkinson's

  https://practicalneurology.com/diseases-diagnoses/movement-disorders/study-shows-promise-for-lrrk2-inhibitor-approach-to-parkinsons/30644/
  Research is focusing on the LRRK2 gene as a means of neuroprotection.
  • Text

• Digital Cognitive Assessments for Dementia

  https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/digital-cognitive-assessments-for-dementia/31728/
  Digital assessments may enhance the efficiency of evaluations in neurology and other clinics.
  • Text
• https://practicalneurology.com/about-practical-neurology/
  Launched in 2002, Practical Neurology® is uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news to facilitate practical application of recent advances in neurology and improve clinical practice for all neuro…

• Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy

  https://practicalneurology.com/live-events/advancing-treat-to-target-care-in-generalized-myasthenia-gravis-earlier-diagnosis-standardized-assessment-and-precision-use-of-fcrn-directed-therapy/56670/
  Through live expert discussion, examine gMG diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy.
  Location: Phoenix, Arizona, United States
  Date: November 5, 2026; 06:30 PM - 08:30 PM MST
  • Broadcast

• Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy

  https://practicalneurology.com/live-events/advancing-treat-to-target-care-in-generalized-myasthenia-gravis-earlier-diagnosis-standardized-assessment-and-precision-use-of-fcrn-directed-therapy/56671/
  Through live expert discussion, examine gMG diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy.
  Location: Houston, Texas, United States
  Date: October 23, 2026; 06:30 PM - 08:30 PM CT
  • Broadcast

• Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy

  https://practicalneurology.com/live-events/advancing-treat-to-target-care-in-generalized-myasthenia-gravis-earlier-diagnosis-standardized-assessment-and-precision-use-of-fcrn-directed-therapy/56673/
  Through live expert discussion, examine gMG diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy.
  Location: Austin, Texas, United States
  Date: October 22, 2026; 06:30 PM - 08:30 PM CT
  • Broadcast

• Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy

  https://practicalneurology.com/live-events/advancing-treat-to-target-care-in-generalized-myasthenia-gravis-earlier-diagnosis-standardized-assessment-and-precision-use-of-fcrn-directed-therapy/56674/
  Through live expert discussion, examine gMG diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy.
  Location: Atlanta, Georgia, United States
  Date: October 24, 2026; 06:30 PM - 08:30 PM ET
  • Broadcast

• Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy

  https://practicalneurology.com/live-events/advancing-treat-to-target-care-in-generalized-myasthenia-gravis-earlier-diagnosis-standardized-assessment-and-precision-use-of-fcrn-directed-therapy/56672/
  Through live expert discussion, examine gMG diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy.
  Location: Miami, Florida, United States
  Date: November 7, 2026; 06:30 PM - 08:30 PM ET
  • Broadcast

• An Exclusive Peer Dinner with Gil I. Wolfe MD, FAAN, Discussing Advancing Treat-to-Target Care in Generalized Myasthenia Gravis

  https://practicalneurology.com/live-events/an-exclusive-peer-dinner-with-gil-i-wolfe-md-faan-discussing-advancing-treat-to-target-care-in-generalized-myasthenia-gravis/56668/
  Limited Seating. Join Gil I Wolfe MD, FAAN, for an intimate dinner discussion at The Capital Grille Rockefeller Center.  We will examine earlier diagnosis, standardized assessment, treat-to-target care, and the integration of FcRn-directed therapy in gMG.
  Location: New York, New York, United States
  Date: October 10, 2026; 05:00 PM - 07:00 PM ET
  • Broadcast
• Montara Therapeutics’ Brain-Selective mTOR Program for Parkinson Disease Receives Michael J. Fox Foundation Funding
  https://practicalneurology.com/news/montara-therapeutics-brain-selective-mtor-program-for-parkinson-disease-receives-michael-j-fox-foundation-funding/2487334/
    KEY TAKEAWAYS Montara Therapeutics received an approximately $1 million research grant from The Michael J. Fox Foundation for Parkinson’s Research. The preclinical program will use Montara’s BrainOnly platform

• Prev
• 1
• 2
• 3
• …
• 140
• 141
• Next